Necrostatin-1

For research use only.

Catalog No.S8037

56 publications

Necrostatin-1 Chemical Structure

Molecular Weight(MW): 259.33

Necrostatin-1 is a specific RIP1 (RIPK1) inhibitor and inhibits TNF-α-induced necroptosis with EC50 of 490 nM in 293T cells. Necrostatin-1 also blocks IDO and suppresses autophagy and apoptosis.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 130 In stock
USD 97 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Necrostatin-1 has been cited by 56 publications

Purity & Quality Control

Choose Selective RIP kinase Inhibitors

Biological Activity

Description Necrostatin-1 is a specific RIP1 (RIPK1) inhibitor and inhibits TNF-α-induced necroptosis with EC50 of 490 nM in 293T cells. Necrostatin-1 also blocks IDO and suppresses autophagy and apoptosis.
Features A powerful tool for characterizing the role of necroptosis with characterized primary target.
Targets
RIP1 [1]
(293T cells)
490 nM(EC50)
In vitro

Necrostatin-1 (1-100 μM) inhibits the autophosphorylation of overexpressed and endogenous RIP1.It is found RIP1 is the primary cellular target responsible for the antinecroptosis activity of Necrostatin-1. [1] Necrostatin-1 efficiently suppresses necroptotic cell death triggered by an array of stimuli in a variety of cell types. Necrostatin-1, previously identified as small-molecule inhibitor of necroptosis, inhibits RIP kinase-induced necroptosis and inhibits TNF-α-induced necroptosis in jurkat cells with EC50 of 490 nM. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A549 NWHIPWZiS2WubDDWbYFjcWyrdImgRZN{[Xl? NHPnToM2OMLizszN NF3HO5EzPMLiaB?= MX\pcohq[mm2czDNUXMucW6mdXPl[EBk\WyuIHTlZZRp NILhTVgzPjR5MkeyNy=>
MEFs  MUjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NY\WR2xyOTEkgJpOwG0> NUPPfFNMPDhiaB?= NFTTOVNFVVOR MVPpcohq[mm2czD6WmFFNXC{b33veIVlKGSnYYToJI9nKEOQT2SzMYRmeGyndHXkJG1GTnN? NULnW3FiOjZ2M{e3PFk>
BMDM  NF3hRXVHfW6ldHnvckBCe3OjeR?= MW[xNOKh|ryP MXKzNOKhdWmw NXr3S|VGeHKxdHXjeJMh[2WubIOg[pJwdSCWQVvJMYlv\HWlZXSgUGRJKHKnbHXhd4U> M4Xze|I3OzhzNkCx
NCI-H28 MXXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M4jTNVExyqEQvF2= NIS0bmozPMLiaB?= M4fMd5Bz\X[nboTzJGRCWEVvaX7keYNm\CC{ZXT1Z5Rqd25ib3[gUmNKNUh{ODDj[YxtKH[rYXLpcIl1gcLi NFX4NlIzPjByNEGzPC=>
MiaPaCa-2 MXXGeY5kfGmxbjDBd5NigQ>? MoDqNlAh|ryP NWXwOVZnOjRiaB?= MorI[IVkemWjc3XzJJRp\SCnYYLsfUBv\WO{b4TpZ{Bk\Wyucx?= NY\OTWRLOjZyMEC2NFc>
BxPC-3 M4mwOGZ2dmO2aX;uJGF{e2G7 MoPONlAh|ryP NWXNTW52OjRiaB?= M2jJZ4Rm[3KnYYPld{B1cGViZXHycJkhdmWlcn;0bYMh[2WubIO= NHzvWWwzPjByME[wOy=>
SGC-7901 MYHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NVLqT3JuOzEEoN88US=> M2HJc|HDqGh? NVfQWYlCe3WycILld5NmeyCxeHHsbZBt[XSrbj3t[YRq[XSnZDDj[YxtKGSnYYTo NVT3VlNiOjV5NkewO|Y>
KMS-12-PE  NYr4V4xCS2WubDDWbYFjcWyrdImgRZN{[Xl? NVi2c|N6PjBizszN MVS1JIg> MlnKbY5pcWKrdIOgV2hMNWmwZIXj[YQh[2WubDDk[YF1cA>? M3G3V|I2PTNyMEm4
L929-A  M17sSmNmdGxiVnnhZoltcXS7IFHzd4F6 M{jEUVUxyqEQvF5CpC=> MkjGNlQhcA>? MkH6Zoxw[2u|IGTOSu6yNWmwZIXj[YQh[2WubDDk[YF1cA>? M2rmW|I2Ozl6NUSw
L929-N  NUjHXodVS2WubDDWbYFjcWyrdImgRZN{[Xl? MlzWOVDDqM7:TdMg NV3qUW5WOjRiaB?= MVficI9kc3NiVF7G{tEucW6mdXPl[EBk\WyuIHTlZZRp NILVcWkzPTN7OEW0NC=>
L929-A  NYHL[ZgxTnWwY4Tpc44hSXO|YYm= MV[1NOKh|ryPwrC= NEj4SFMyOiCq NFG4WnNjdG:la4OgeIhmKGOuZXH2ZYdmKG:oIFPhd5Bie2VvMzDhcoQhWEGUUB?= NFTQWWMzPTN7OEW0NC=>
L929-N  M3XF[GZ2dmO2aX;uJGF{e2G7 MlToOVDDqM7:TdMg MVGxNkBp M4nvfIJtd2OtczD0bIUh[2ynYY\h[4Uhd2ZiQ3HzdIF{\S1|IHHu[EBRSVKS NEi5RpkzPTN7OEW0NC=>
L929 NVfWNWxnTnWwY4Tpc44hSXO|YYm= NVH3UmFOPTEEoN88UeKh NVXsVWtCOTJiaB?= M2D3bIlvcGmkaYTzJHRPTs7zLXnu[JVk\WRiQnnkJINt\WG4YXfl NEDoV3UzPTN7OEW0NC=>
L929-A MVjGeY5kfGmxbjDBd5NigQ>? MnHCOVDDqM7:TdMg MXSxNkBp Mmf4bY5pcWKrdIOgeIhmKFSQRt8xMYlv\HWlZXSgcI9{eyCxZjDtbZRw[2ixbnTybYFtKG2nbXLyZY5mKHCncn3lZYJqdGm2eR?= M4jPZ|I2Ozl6NUSw
L929 NEjFeY1E\WyuIG\pZYJqdGm2eTDBd5NigQ>? Mn\NN|DDqM7:TR?= NXvjfGNSOcLiaB?= M{KyOYlvcGmkaYTzJHRPTi4QsT3pcoR2[2WmIHzvd5Mhd2ZiY3XscEB3cWGkaXzpeJk> Mn7XNlUxQTV5NEK=
L929 M3rJdGNmdGxiVnnhZoltcXS7IFHzd4F6 M4LZ[|MxyqEQvF2= MlvTNeKhcA>? MXvpcohq[mm2czDUUmYu|rFvaX7keYNm\CClbHXheoFo\SCxZjDUc5BwKEl? NGnHdlgzPTB7NUe0Ni=>
Huh7 NUDIOIZSS2WubDDWbYFjcWyrdImgRZN{[Xl? NVnmeHp6PTBiwsXN NGTTdVIzPC92ODDo MXXEUXNQ M3XlOJBz\X[nboTzJINmdGxiZHXheIghd2ZiclHkTGNXKGOxLXnu[oVkfGWmIFj1bFch[2WubIO= NUP5VpczOjR7N{OyOFA>
OHC MoraSpVv[3Srb36gRZN{[Xl? MYqzNFDjiIoQvF2= NXrDO4l3TE2VTx?= M4LXeolv[3KnYYPld{Bvd2m|ZT3pcoR2[2WmIHPvcoRmdnOnZDDueYNt\Wl? MnrxNlQ5PzR5M{S=
OHC NIDPN21HfW6ldHnvckBCe3OjeR?= NHvQTGU{ODEkgJpOwG0> MXHEUXNQ NHzXdppl\WO{ZXHz[ZMhdm:rc3WtbY5lfWOnZDDze49tdGWwIH71Z4xmccLi NYXod4Z{OjR6N{S3N|Q>
OHC M1jaOGZ2dmO2aX;uJGF{e2G7 M3Kzb|MxOOLCid88US=> MYrEUXNQ MlrCdoV{fWy2czDpckBiKHKnZIXjeIlwdiCxZjDuc4l{\S2rbnT1Z4VlKFKLUEGgZY5lKFKLUEOgbY1ufW6xZnz1c5Jme2OnbnPl NUjhem9OOjR6N{S3N|Q>
OHC NV3WeWVCTnWwY4Tpc44hSXO|YYm= NH3Ne2o{ODEkgJpOwG0> M1vrWGROW09? NUf2T29M\GmvaX7pd4hmeyCwb3nz[U1qdmS3Y3XkJGFOWEtiYXP0bZZifGmxbh?= MkKxNlQ5PzR5M{S=
OHC MXvGeY5kfGmxbjDBd5NigQ>? NID1[|U{ODEkgJpOwG0> NHLEVIpFVVOR M2\KWIlv[3KnYYPld{B1cGViboXtZoVzKG:oIHHwc5B1d3SrYzDPTGN{KHerdHjveZQh[Wy2ZYLpcochfGinIHzleoVteyCxZjDDR|gh[W[2ZYKgco9qe2ViZYjwc5N2emV? M{nUWFI1QDd2N{O0
SK-Hep1 Ml7ISpVv[3Srb36gRZN{[Xl? MkLMOlDjiIoQvF5CpC=> NXvh[5BTOTkkgJno NIPER|djdG:la4RCpO6zNWyjcHHjbI9v\S2rbnT1Z4VlKG2xcoDoc4xw\2mlYXygZ4hidmenLDDj[YxtKGSnYYToJIFv\CCSSTD1dJRic2V? MmLsNlQ5OzJ4MEK=
SK-Hep1 NUP2dIYyTnWwY4Tpc44hSXO|YYm= NWH3T2hRPjEkgJpOwG3DqA>? NXvHXms1OTkkgJno NHrpNFNqdmirYnn0d{DPui2OYYDhZ4hwdmVvaX7keYNm\CCuZXHrZYdmKG:oIFjNS2IuOcLi NHO3[HMzPDh|Mk[wNi=>
SK-Hep1 MojLSpVv[3Srb36gRZN{[Xl? NXSxRYZvPjEkgJpOwG3DqA>? MoOyNVjjiImq M1;CboJtd2Otc9Mg{tIudGGyYXPoc45mNW2nZHnheIVlKFCDUjDhZ4N2dXWuYYTpc44h[W6mIFHJSkB1emGwc3zvZ4F1cW:wIITvJJRp\SCleYTvd49tyqB? MYGyOFg{OjZyMh?=
L-540  NYjEWZNpTnWwY4Tpc44hSXO|YYm= NUKzXZQ{PjEkgJpOwI0> NXfueIt2OeLCiXi= MkG4dJJmfmWwdIOgeIhmKGenbnXyZZRqd25ib3[gVm9U M3TXOlI1PTZzNUG5
L-540  NVn2ZpRFTnWwY4Tpc44hSXO|YYm= MWC2NQKBkc7:bR?= M1Xoe|HjiImq M2fHPJBz\X[nboTzJJRp\SCvaYTvZ4hwdmS{aXHsJI1mdWK{YX7lJIRmeG:uYYLpfoF1cW:w M3vTcFI1PTZzNUG5
L-540  NE\peItE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M3H6dVYx6oDLzszt MmTLNgKBkWh? MWPy[YR2[2W|IITo[UBIcX[rbn;zeIF1N1OxcnHm[Y5q[i2rbnT1Z4VlKGOnbHyg[IVifGh? NYDTdGE{OjR3NkG1NVk>
AGS NXjRXWRKS2WubDDWbYFjcWyrdImgRZN{[Xl? NIXzS5U3OOLCid88cS=> MlfkNgKBkWh? NGDkS3FxemW4ZX70d{B{cGmtb37pck1qdmS3Y3XkJINmdGxiZHXheIg> NF[3SGozPDR4M{G5PS=>
NRK-52E  M4rjN2NmdGxiVnnhZoltcXS7IFHzd4F6 MWCyNEDPxE1? NIm3UXkzPCCq NF;jNVZxem:2ZXP0d{Bk\WyuczDmdo9uKGOnbHyg[IVifGhiY3H1d4VlKGK7IHnzZ4hmdWmjIHnubpVzgQ>? Ml3QNlQ{PTF6NEW=
NRK-52E  NHHIT3ZE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M1;qR|IxKM7:TR?= M1PJOVI1KGh? M17Obolv[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDh[pRmeiCWTl[t{tEhW3SrbYXsZZRqd25iYX7kJGFVWCCGZYDs[ZRqd25? NWnZNG17OjR|NUG4OFU>
NRK-52E  MYnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NETBVYQzOCEQvF2= MUGyOEBp M1rDZYlvcGmkaYTzJIlv[3KnYYPl[EBFenBzIIDyc5RmcW5iZYjwdoV{e2mxbjDh[pRmeiCWTl[t{tEhW3SrbYXsZZRqd25iYX7kJGFVWCCGZYDs[ZRqd25? Mlr2NlQ{PTF6NEW=
L929 NF7mZohHfW6ldHnvckBCe3OjeR?= MnXPNk82yqEQvHevcYzDqA>? NXLnRmQ6OjUEoHi= NVOw[G9GemW4ZYLz[YQhfGinIHH1eI9xcGGpeTDpcoR2[2WmIHL5JHRPTs7zIHHsc45mKGG|IIflcIwh[XNiVF7G{tHDqCwEoIrWRWQ> MVmyN|k1OTd4OR?=
L929 NFHhdGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUOyM|XDqM7:Zz;tcOKh NHXDWlkzPMLiaB?= M2fCTpJmfmW{c3XzJJRp\SClZXzsJIdzd3e2aDDpcohq[mm2aX;uJIFv\CClZXzsJIRm[XSqIHnu[JVk\WRiYomgWG5H|rFiYXzvcoUh[XNid3XscEBieyCWTldOteKhM8Liem\BSC=> M3LCe|I{QTRzN{[5
L929 MULGeY5kfGmxbjDBd5NigQ>? MlHuNuKh|rypL33sxsA> NVnSU3JJOjUEoHi= NXnOfVZ6eHKxbX;0d{Bk[XOyYYPlMVYhMHB{MDmgZYN1cX[rdImgZY5lKHC{b3Phd5Bie2VvNjDjcIVifmGpZR?= NUfB[2lCOjN7NEG3Olk>
L929 MmOxSpVv[3Srb36gRZN{[Xl? M4q4cFXDqM7:Zz;tcC=> Mnn2NlTDqGh? M4TVWoJtd2OtczD6WmFFKGmwZIXj[YQhdmWlcn;weI9{cXNiYX7kJIF2fG:yaHHnfS=> MYCyN|k1OTd4OR?=
C6 NUS1V2p7S2WubDDWbYFjcWyrdImgRZN{[Xl? NFn5N5AyKG2vb3yvUC=> M1e5UVMhcA>? NEGwNHNifHSnboXheIV{KFOqaXvvcolvKGmwZIXj[YQh\2yrb33hJINmdGxiZHXheIg> NXjiNotCOjN6NEC0OFE>
U87 MVzD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MV[xJI1ud2xxTB?= NXPSfVQ6OyCq Ml[wZZR1\W63YYTld{BUcGmtb37pckBqdmS3Y3XkJIdtcW:vYTDj[YxtKGSnYYTo NYPoWY5JOjN6NEC0OFE>
C6 MlTJR5l1d3SxeHnjbZR6KEG|c3H5 MoiwNUBudW:uL1y= M2\nS|MhcA>? Ml3YZoxw[2u|IIPobYtwdmmwIHnu[JVk\WRibnXjdo9{cXN? M1jzXlI{QDRyNESx
U87 Ml71R5l1d3SxeHnjbZR6KEG|c3H5 NHjIe5kyKG2vb3yvUC=> M1XXOVMhcA>? M4XDWYJtd2OtczDzbIlsd26rbjDpcoR2[2WmIH7lZ5Jwe2m| M2\lZVI{QDRyNESx
C6 MWHGeY5kfGmxbjDBd5NigQ>? NXXNRWNoOSCvbX;sM2w> M2Hie|EvPS1|IHi= MVXzeZBxemW|c3XzJJRp\SCneIDy[ZN{cW:wIH;mJHJKWC1zIHPheZNm\CCkeTDzbIlsd26rbh?= NVTjUHVnOjN6NEC0OFE>
U87 NFT0eVJHfW6ldHnvckBCe3OjeR?= MmfQNUBudW:uL1y= NXPnW|NtOS53LUOgbC=> MVPzeZBxemW|c3XzJJRp\SCneIDy[ZN{cW:wIH;mJHJKWC1zIHPheZNm\CCkeTDzbIlsd26rbh?= M{fpNFI{QDRyNESx
TE671 MlfaR4VtdCCYaXHibYxqfHliQYPzZZk> NEPSO4Q1OOLCid88[{9udMLi NGHjUJEzPCCq MXPy[ZNkfWW|IFfYNVUuODdyLXnu[JVk\WRibH;zd{Bw\iClZXzsJJZq[WKrbHn0fS=> Mn7KNlM4PDR{OU[=
RMS13 MVHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NYT5PXdkPDEkgJpOwIcwdW{EoB?= MXWyOEBp NF7oVXNz\XOldXXzJGdZOTVvMEewMYlv\HWlZXSgcI9{eyCxZjDj[YxtKH[rYXLpcIl1gQ>? MljyNlM4PDR{OU[=
MEFs NVnpTpVjS3m2b4TvfIlkcXS7IFHzd4F6 NYnRV4F6Oi94L{KwJO69VQ>? NEG4fpcyQCCq NHK0cWFqdmirYnn0d{BVVkcQsT3pcoR2[2WmIHPlcIwh\GWjdHigbY4hWmWuQTDLU{BOTU[| M3zJb|I{PzJ5NUix
MEFs NXKyNlU6TnWwY4Tpc44hSXO|YYm= M2LTTVIxyqEQvF2= M2rwelEwOi92IHi= NUjSPG5le3WycILld5NmeyCWTldOtU1qdmS3Y3XkJHJKWEtzIIDoc5NxcG:{eXzheIlwdg>? M{fCdFI{PzJ5NUix
ΔN-Karpas 299  NFjSbZlEgXSxdH;4bYNqfHliQYPzZZk> NFfTblQzOMLizszN MonXNVYhcA>? MoTybY5pcWKrdIOgR2Q{OC2rbnT1Z4VlKGOnbHyg[IVifGh? MmrhNlM2PDV7M{i=
MM.1S  M3nJOGN6fG:2b4jpZ4l1gSCDc4PhfS=> MW[5NEDDvU1? MV6xJIg> NFLJXJJjdG:la4OgRmF[KDFzLUewPFIhcW6mdXPl[EBz[XCrZDDj[YxtKHO5ZXzsbY5o MoHnNlM2OjdzNUS=
KMS-12-BM MVXDfZRwfG:6aXPpeJkhSXO|YYm= NXvpTnZzQTBiwsXN NUHVU2gxOSCq MUnicI9kc3NiQlHZJFEyNTdyOEKgbY5lfWOnZDDyZZBq\CClZXzsJJN4\WyuaX7n Mn\ZNlM2OjdzNUS=
HT-22  NV\C[GlrS2WubDDWbYFjcWyrdImgRZN{[Xl? MlrUNVDDqM7:TR?= MnPwNVLDqGh? MVHEUXNQ M3Pjb5Bzd3SnY4TzJIFo[Wmwc4Sg[4x2fGGvYYTlMYlv\HWlZXSgZ4VtdCCmZXH0bC=> MX6yN|MxPzd3Mh?=
HT-22  NIDqNlFHfW6ldHnvckBCe3OjeR?= M3TTWVI2yqEQvF2= NXfSXJFSOOLCk{OwxsBucW5? M{fTO2ROW09? MlftbY5pcWKrdIOgSXJMKEGldHn2ZZRqd25iaX7keYNm\CCkeTDncJV1[W2jdHW= M4nxZVI{OzB5N{Wy
NIH3T3  NYHZbFkyTnWwY4Tpc44hSXO|YYm= MlvQNVAwPTBizszN NWq2W49oOS9|IHi= NHm1U|ZidWWuaX;yZZRmeyCWTldOtU1lemm4ZX6gZ49ueGyneDDmc5Ju[XSrb36= MVKyN|I3OTZ5Nx?=
SH-EP M{W1eGFxd3C2b4Ppd{BCe3OjeR?= NFfmOIQyOOLCid88UeKh M3XBPFcz6oDLaNMg M3:xWIlvcGmkaYTzJGlCWCCrbnjpZol1d3JvIHHu[EBN\XijdIXteY1i[i2rbnT1Z4VlKGGyb4D0c5Nqew>? NXvsfmk4OjJ6OUCzNlI>
HL60 NF3BRXdCeG:ydH;zbZMhSXO|YYm= MlLBOlAh|ryP M2\WPVEzKGh? NI\1cJVmdmijbnPld{B{cGmtb37pck1qdmS3Y3XkJIFxd3C2b4Ppdy=> MVWyNlg{PzZ6OR?=
HL60/Adr M1frNGFxd3C2b4Ppd{BCe3OjeR?= NYPBZZRXPjBizszN Mo\zNVIhcA>? MkLG[Y5p[W6lZYOgd4hqc2:waX6tbY5lfWOnZDDhdI9xfG:|aYO= NWqzU41IOjJ6M{e2PFk>
K562 MXPBdI9xfG:|aYOgRZN{[Xl? M1[1SFYxKM7:TR?= MYWxNkBp M2nse4VvcGGwY3XzJJNpcWuxbnnuMYlv\HWlZXSgZZBweHSxc3nz NXrvdlF1OjJ6M{e2PFk>
K562/Adr  NVr0c4ZJSXCxcITvd4l{KEG|c3H5 MlTaOlAh|ryP M{nvWVEzKGh? NYrSSHJ4\W6qYX7j[ZMhe2ira3;ubY4ucW6mdXPl[EBieG:ydH;zbZM> MVGyNlg{PzZ6OR?=
HL60 MWnGeY5kfGmxbjDBd5NigQ>? NYHVPWd5PjBizszN Mlj6NVIhcA>? NIfWeJFifWevZX70d{B1cGViY3HzdIF{\S1|IHHjeIl3cXS7 M2S3RlIzQDN5Nki5
HL60/Adr NUX4NYZvTnWwY4Tpc44hSXO|YYm= M1rZcVYxKM7:TR?= MUixNkBp NWXSR21E[XWpbXXueJMhfGinIHPhd5Bie2VvMzDhZ5Rqfmm2eR?= MYeyNlg{PzZ6OR?=
K562 NVHkUWVCTnWwY4Tpc44hSXO|YYm= MUC2NEDPxE1? NGH3W2wyOiCq NUHRfllE[XWpbXXueJMhfGinIHPhd5Bie2VvMzDhZ5Rqfmm2eR?= M1j0OFIzQDN5Nki5
K562/Adr  Mki2SpVv[3Srb36gRZN{[Xl? NHTseJg3OCEQvF2= MmPuNVIhcA>? NWrrdIYy[XWpbXXueJMhfGinIHPhd5Bie2VvMzDhZ5Rqfmm2eR?= MmDnNlI5Ozd4OEm=
HL60 MUjGeY5kfGmxbjDBd5NigQ>? NUXjPGhMPjBizszN NG\ofXYyOiCq MXTpcoNz\WG|ZYOgeIhmKGGldHn2bZR6KG:oIHPhd5Bie2W|LDDjZZNx[XOnIEigZY5lKDl? MmGzNlI5Ozd4OEm=
HL60/Adr M{LRfWZ2dmO2aX;uJGF{e2G7 MYe2NEDPxE1? NF64ToIyOiCq MV;pcoNz\WG|ZYOgeIhmKGGldHn2bZR6KG:oIHPhd5Bie2W|LDDjZZNx[XOnIEigZY5lKDl? NEnWdYIzOjh|N{[4PS=>
K562 MWXGeY5kfGmxbjDBd5NigQ>? NIq3O|Q3OCEQvF2= MoSyNVIhcA>? MlTxbY5kemWjc3XzJJRp\SCjY4Tpeol1gSCxZjDjZZNx[XOnczygZ4F{eGG|ZTC4JIFv\CB7 M3\wNlIzQDN5Nki5
K562/Adr  NVnx[FBOTnWwY4Tpc44hSXO|YYm= MmLmOlAh|ryP NUnVOHB7OTJiaB?= MV7pcoNz\WG|ZYOgeIhmKGGldHn2bZR6KG:oIHPhd5Bie2W|LDDjZZNx[XOnIEigZY5lKDl? M3f6S|IzQDN5Nki5
L929sA MoDqRZBweHSxc3nzJGF{e2G7 NFfybmkyOCEQvF2= MWOxJIg> MXfpcohq[mm2czD0bIUh[XCxcITveIlkKHKnc4DvcpNmKHSxIGTOSi=> M1[4clIzOzZ{N{[3
L929sA MkHQRZBweHSxc3nzJGF{e2G7 MnrlNVAh|ryP NWP5NWNnOSCq M2TXSJJme2O3ZYOgZ4VtdHNiZYjwdoV{e2mwZzDSTXBMOc7WSVSg[pJwdSCWTl[tbY5lfWOnZDDhdI9xfG:|aYO= NHX1boQzOjN4Mke2Oy=>
L929sA NFHDeG1CeG:ydH;zbZMhSXO|YYm= MVuxNEDPxE1? NF33eWwyKGh? MojwZYJzd2ejdHXzJJRp\SCrboTldoFkfGmxbjDv[kBk[XOyYYPlMVghf2m2aDDGRWRF NFjQc|EzOjN4Mke2Oy=>
TPC-1 MXrD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MVyxNFAh|ryP MmjNNlQhcA>? MV\EUXNQ NUTR[XhMcW6lcnXhd4V{KGOnbHz1cIFzKHO3co\peoFt MnLUNlIyOzZ6MUi=
8505c NG\HVppE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MXuxNFAh|ryP M3i2ZlI1KGh? MlfySG1UVw>? MXLpcoNz\WG|ZYOgZ4VtdHWuYYKgd5Vzfmm4YXy= MmHnNlIyOzZ6MUi=
SW13 MYrD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M2rie|ExOCEQvF2= M2jhOlI1KGh? M4Xub2ROW09? NGL3emZqdmO{ZXHz[ZMh[2WubIXsZZIhe3W{dnn2ZYw> M{WwU|IzOTN4OEG4
Jurkat  M3\pb2N6fG:2b4jpZ4l1gSCDc4PhfS=> MVi1NE8hOTByL{KwNOKh|ryv MkjuNU8{KGh? NYfhXIw3emWmdXPld:KhVmGnZ3zldoliKG[xd3zldokucW6mdXPl[EBkgXSxdH;4bYNqfHl? M1nD[|IyPTN3MEKw
Jurkat  NE\0No5HfW6ldHnvckBCe3OjeR?= MX2yNFDDqM7:bR?= MV[zNEBucW5? MV;y[YR2[2W|wrDOZYVodGW{aXGg[o94dGW{aT3pcoR2[2WmIILlZYN1cX[nIH;4fYdmdiC|cHXjbYV{KCiUT2OpJIdmdmW{YYTpc44> MV:yNVU{PTB{MB?=
HT-22 NGfHS2lEgXSxdH;4bYNqfHliQYPzZZk> NVzxPHBjOTBizszN M{jablEzKGh? NGPsUJJxem:2ZXP0d{Bi\2GrboP0JINmdGxiZHXheIghcW6mdXPl[EBjgSB3wrDtcY9tN0xiZ3z1eIFu[XSnwrC= MV6xO|c3ODh4OR?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Immunofluorescence
RIP1 / RIP3 ; 

PubMed: 30462730     


Immunofluorscence data showed an increased expression of RIP1 and RIP3 in Pg-LPS group and an eminent reduction of RIP1 in the Pg-LPS+Nec-1 group.

30462730

Protocol

Kinase Assay:

[1]

- Collapse

RIP1 kinase assay:

Phosphorylation of RIP1 requires its kinase activity. Expression constructs of FLAGtagged wild-type (WT) or a kinase-inactive pointmutant of RIP1 (K45M) are are transfected into 293T cells and RIP1 kinase assay is performed as described in the Methods in the presence of [γ-32P]ATP for 30 min at 30℃. Samples are subjected to SDS-PAGE and RIP1 band is visualized by autoradiography. Relative intensities of radioactive bands are quantified and are shown (ratio) in this and all other autoradiographs. In parallel to kinase reactions, a sample of beads is subjected to western blot analysis using anti-RIP1 antibody to ensure equal protein amounts in kinase reactions.
Cell Research:

[2]

- Collapse
  • Cell lines: Jurkat, BALB/c 3T3, SV40-transformed MEF, L929
  • Concentrations: 0.01-100 μM
  • Incubation Time: --
  • Method:

    Cells are seeded in 96-well plates (white plates for luminescent assays; black plates for fluorescent assays; clear plates for MTT assay) at the density of 5,000-10,000 cells per well for adherent cells or 20,000-50,000 cells per well for suspension cells in 100 μl of the appropriate phenol red-free media. After incubation, we determined cell viability using one of the following methods. For the ATP assay, we used luminescence-based commercial kits and analyzed luminescence using a Wallac Victor II plate reader. For Sytox assay, we incubated cells with 1 μM Sytox Green reagent for 30 min at 37℃, and then performed fluorescent reading. Subsequently, we added 5 μl of 20% Triton X-100 solution into each well to produce maximal lysis and incubated cells for 1 h at 37℃, then performed the second reading. We calculated the ratio of values before and after Triton treatment and normalized it to the relevant controls not subjected to cytotoxic stimuli, as indicated in figure legends. For the MTT assay, we used the CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay kit. For PI exclusion assays, we added 2 μg/ml PI into the medium and immediately analyzed samples using FACSCalibur. For PI-annexin V assay we used the ApoAlert Annexin V-EGFP Apoptosis Kit. For DioC6 staining, we incubated cells with 40 nM DiOC6 for 30 min at 37 ℃, washed once and analyzed in FACSCalibur. For ROS analysis, we incubated cells with 5 μM dihydroethidium for 30 min at 37 ℃, washed once and analyzed in FACSCalibur. EM analyses are performed at the Harvard Medical School EM facility. We acquired bright-field images of the cells using an Axiovert 200 microscope.


    (Only for Reference)

Solubility (25°C)

In vitro DMSO 51 mg/mL warmed (196.66 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+45% PEG 300+ddH2O
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 259.33
Formula

C13H13N3OS

CAS No. 4311-88-0
Storage powder
in solvent
Synonyms N/A
Smiles CN1C(=O)C(NC1=S)CC2=CNC3=CC=CC=C32

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field
Tags: buy Necrostatin-1 | Necrostatin-1 supplier | purchase Necrostatin-1 | Necrostatin-1 cost | Necrostatin-1 manufacturer | order Necrostatin-1 | Necrostatin-1 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID